India Pharma Outlook Team | Saturday, 12 July 2025
In a bold strategic shift, Wockhardt has divested its US generics business to focus on high-value, innovative therapies, including novel antibiotics and biologics.
The company announced the voluntary liquidation of Wockhardt USA LLC and Morton Grove Pharmaceuticals Inc., two U.S.-based wholly owned subsidiaries after continued, unprofitable performance in a heavily commoditized sector of the U.S. generics market.
Wockhardt USA LLC reported a net loss of nearly USD 8 million in FY25 from generics, driving the decision to reallocate financial and human resources towards research-led growth.
With this exit from the U.S. generics business, the company is reaffirming commitment to its antibiotic pipeline, including key candidates Zaynich (WCK 5222) and Miqnaf, which target antimicrobial resistant organisms. Zaynich has potential in the global market at USD 7 billion and is an important anchor to the company's global innovation plans.
Also Read: Building a Successful Pharma Brand in India: The Role of Scientific Communication
At the same time, Wockhardt is expanding its biologics related to insulin for India and other emerging markets, as global suppliers decrease their investments in traditional offerings.
The decision represents a commitment to Wockhardt's vision of becoming a science-driven, innovation-first pharmaceutical company. The intention is to diversify portfolios away from low-margin products, and instead create sustainable and differentiated portfolios. The company will continue to focus on operations in India, U.K., Ireland and emerging markets, performance remains strong.
Investors welcomed the move, with Wockhardt shares rising over 3.5%, reflecting market confidence in the company’s future-forward strategy and innovation-led roadmap.
